

The following table shows the financial results for Merck & Co., Inc. and subsidiaries for the quarter ended June 30, 2008, compared with the corresponding period of the prior year.

Merck & Co., Inc.  
Consolidated Results  
(In Millions Except Earnings per Common Share)  
Quarter Ended June 30  
(Unaudited)

	<u>2008</u>	<u>2007</u>	<u>% Change</u> (1)%
Sales	\$6,051.8	\$6,111.4	
Costs, Expenses and Other			
Materials and production <sup>(1)</sup>	1,396.5	1,552.3	(10)
Marketing and administrative <sup>(2)</sup>	1,930.2	2,083.7	(7)
Research and development	1,169.3	1,030.5	13
Restructuring costs <sup>(3)</sup>	102.2	55.8	83
Equity income from affiliates	(523.0)	(759.1)	(31)
Other (income) expense, net	(81.9)	(84.0)	(2)
Income Before Taxes	2,058.5	2,232.2	(8)
Taxes on Income <sup>(4)</sup>	290.2	555.8	
Net Income	\$1,768.3	\$1,676.4	5
Average Shares Outstanding			
Assuming Dilution	2,154.3	2,189.2	
Earnings per Common Share			
Assuming Dilution	\$0.82	\$0.77	6

(1) Includes restructuring costs of \$16.1 million in the second quarter of 2008 and \$118.7 million in the second quarter of 2007 primarily related to accelerated depreciation associated with Merck's global restructuring program announced in November 2005.

(2) Includes the impact of reserving an additional \$210 million in the second quarter of 2007 solely for future legal defense costs for VIOXX litigation.

(3) Restructuring costs represent separation and other related costs associated with the global restructuring program.

(4) The second quarter 2008 effective tax rate was 14.1%. The effective tax rate excluding the impact of restructuring charges was 15.2%. Both rates reflect a second quarter net benefit of approximately nine percentage points primarily relating to the favorable impact of tax settlements.

The following table shows the financial results for Merck & Co., Inc. and subsidiaries for the six months ended June 30, 2008, compared with the corresponding period of the prior year.

Merck & Co., Inc.  
Consolidated Results  
(In Millions Except Earnings per Common Share)  
Six Months Ended June 30  
(Unaudited)

	<u>2008</u>	<u>2007</u>	<u>% Change</u> --%
Sales	\$11,873.9	\$11,880.7	
Costs, Expenses and Other			
Materials and production <sup>(1)</sup>	2,634.6	3,078.1	(14)
Marketing and administrative <sup>(2)</sup>	3,784.7	3,885.7	(3)
Research and development	2,247.6	2,060.6	9
Restructuring costs <sup>(3)</sup>	171.9	121.6	41
Equity income from affiliates	(1,175.1)	(1,411.7)	(17)
Other (income) expense, net <sup>(4)</sup>	(2,259.2)	(340.2)	*
Income Before Taxes	6,469.4	4,486.6	44
Taxes on Income <sup>(5)</sup>	1,398.6	1,105.9	
Net Income	\$5,070.8	\$3,380.7	50
Average Shares Outstanding Assuming Dilution	2,165.8	2,183.4	
Earnings per Common Share Assuming Dilution	\$2.34	\$1.55	51

\* > 100%

(1) Includes restructuring costs of \$31.0 million in the first six months of 2008 and \$236.8 million in the first six months of 2007 primarily related to accelerated depreciation associated with Merck's global restructuring program announced in November 2005.

(2) Includes the impact of reserving an additional \$40 million in 2008 solely for future legal defense costs for FOSAMAX litigation and \$210 million in 2007 solely for future legal defense costs for VIOXX.

(3) Restructuring costs represent separation and other related costs, as well as gains on sales of facilities and related assets in 2008, associated with the global restructuring program.

(4) Other (income) expense, net in the first six months of 2008 reflects a \$2.2 billion gain related to a distribution from AstraZeneca LP, a \$300 million expense for a contribution to The Merck Company Foundation, a \$249 million gain on the Company's remaining worldwide rights to AGGRASTAT and a \$58 million charge in connection with the resolution of an investigation into whether the Company violated state consumer protection laws with respect to the sales and marketing of VIOXX. Other (income) expense, net in the first six months of 2007 primarily reflects the favorable impact of gains on sales of assets and product divestitures.

(5) The effective tax rate was 21.6% for the first six months of 2008. The effective tax rate excluding the impacts of the gain on distribution from AstraZeneca LP and restructuring charges was 14.9% reflecting a net benefit of approximately eight percentage points primarily relating to the favorable impact of tax settlements and the realization of foreign tax credits.